Kuniyuki Aso

Kuniyuki Aso

Auto-generated profile, based on publicly available information

Kuniyuki Aso

Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Sapporo Medical University School of Medicine , Sapporo

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
KAKuniyuki Aso
Kuniyuki Aso
MKMichihito Kono
Michihito Kono
MKMasatoshi Kanda
Masatoshi Kanda
YKYuki Kudo
Yuki Kudo
KSKodai Sakiyama
Kodai Sakiyama
TATatsuya Atsumi
Tatsuya Atsumi
Dysregulation of Th17 and Treg cells contributes to the pathophysiology of many autoimmune diseases. Herein, we show that itaconate, an immunomodulatory metabolite, inhibits Th17 cell differentiation and promotes Treg cell differentiation by orchestrating metabolic and epigenetic reprogramming. Mechanistically, itaconate suppresses glycolysis and oxidative phosphorylation in Th17- and Treg-polarizing T cells. Following treatment with itaconate, the S-adenosyl-L-methionine/S-adenosylhomocysteine ratio and 2-hydroxyglutarate levels are decreased by inhibiting the synthetic enzyme activities in Th17 and Treg cells, respectively. Consequently, these metabolic changes are associated with altered chromatin accessibility of essential transcription factors and key gene expression in Th17 and Treg cell differentiation, including decreased RORγt binding at the Il17a promoter. The adoptive transfer of itaconate-treated Th17-polarizing T cells ameliorates experimental autoimmune encephalomyelitis. These results indicate that itaconate is a crucial metabolic regulator for Th17/Treg cell balance and could be a potential therapeutic agent for autoimmune diseases.

24 January 2023 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
KKKohei Karino
Kohei Karino
MKMichihito Kono
Michihito Kono
STShuhei Takeyama
Shuhei Takeyama
YKYuki Kudo
Yuki Kudo
MKMasatoshi Kanda
Masatoshi Kanda
TATatsuya Atsumi
Tatsuya Atsumi

7 July 2020 in Lupus
Verified
Journal Article
Closed access
PDF file
KAKuniyuki Aso
Kuniyuki Aso
MKMichihiro Kono
Michihiro Kono
TWToshiyuki Watanabe
Toshiyuki Watanabe
YSYuka Shimizu
Yuka Shimizu
YOYusuke Ogata
Yusuke Ogata
TATatsuya Atsumi
Tatsuya Atsumi
This study aimed to explore the risk factors for ‘severe’ neuropsychiatric (NP) flare in patients with systemic lupus erythematosus (SLE). This retrospective study comprised newly diagnosed 184 adult SLE patients who visited Hokkaido University Hospital between 2006 and 2017. In this study, severe NP flare was defined as the occurrence of at least one newly developed British Isles Lupus Assessment Group A score in the neurological domain. Overall severe NP flare-free survival was estimated by Kaplan–Meier analysis. Clinical and demographic profiles at SLE diagnosis were assessed as potential risk items in the adjusted multivariate Cox regression model. The median follow-up period was 7.9 years (interquartile range (IQR) 4.6–12.3) years. A total of 28 (15.2%) patients had one or more severe NP flares during the observation period. The median time from patient enrolment date to severe NP flare occurrence was 3.1 years (IQR 0.9–6.3 year). The 2- and 10-year severe NP flare-free survival rates were 92.7% and 86.0%, respectively. Among the manifestations of severe NP flare, psychosis was the most frequent (19.1%). In the multivariate model, low serum levels of C4 (hazard ratio (HR) = 3.67, p = 0.013) and severe NP manifestations at SLE diagnosis (HR = 7.11, p < 0.001) emerged as independent risk factors for developing severe NP flare. The first severe NP flare presented early in the course of SLE. Low C4 level and severe NP manifestations at SLE diagnosis could predict the development of severe NP flare.

17 March 2023 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
KAKuniyuki Aso
Kuniyuki Aso

31 December 2022 in Gastroenterology
Verified
Journal Article
Closed access
KAKuniyuki Aso
Kuniyuki Aso
HKHideki Kasahara
Hideki Kasahara

16 January 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
KAKuniyuki Aso
Kuniyuki Aso
YFYuichiro Fujieda
Yuichiro Fujieda
TATatsuya Atsumi
Tatsuya Atsumi